title: 14-3-3η Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis.
abstract: OBJECTIVE
  To describe the expression and diagnostic use of 14-3-3η autoantibodies in early rheumatoid arthritis (RA).
  
  
  METHODS
  14-3-3η autoantibody levels were measured using an electrochemiluminescent multiplexed assay in 500 subjects (114 disease-modifying antirheumatic drug-naive patients with early RA, 135 with established RA, 55 healthy, 70 autoimmune, and 126 other non-RA arthropathy controls). 14-3-3η protein levels were determined in an earlier analysis. Two-tailed Student t tests and Mann-Whitney U tests compared differences among groups. Receiver-operator characteristic (ROC) curves were generated and diagnostic performance was estimated by area under the curve (AUC), as well as specificity, sensitivity, and likelihood ratios (LR) for optimal cutoffs.
  
  
  RESULTS
  Median serum 14-3-3η autoantibody concentrations were significantly higher (p < 0.0001) in patients with early RA (525 U/ml) when compared with healthy controls (235 U/ml), disease controls (274 U/ml), autoimmune disease controls (274 U/ml), patients with osteoarthritis (259 U/ml), and all controls (265 U/ml). ROC curve analysis comparing early RA with healthy controls demonstrated a significant (p < 0.0001) AUC of 0.90 (95% CI 0.85-0.95). At an optimal cutoff of ≥ 380 U/ml, the ROC curve yielded a sensitivity of 73%, a specificity of 91%, and a positive LR of 8.0. Adding 14-3-3η autoantibodies to 14-3-3η protein positivity enhanced the identification of patients with early RA from 59% to 90%; addition of 14-3-3η autoantibodies to anticitrullinated protein antibodies (ACPA) and/or rheumatoid factor (RF) increased identification from 72% to 92%. Seventy-two percent of RF- and ACPA-seronegative patients were positive for 14-3-3η autoantibodies.
  
  
  CONCLUSIONS
  14-3-3η autoantibodies, alone and in combination with the 14-3-3η protein, RF, and/or ACPA identified most patients with early RA.
authors.affiliation: From the Department of Medicine, University of Alberta, Edmonton, Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University of Toronto, Toronto; Augurex Life Sciences Corp., North Vancouver, British Columbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam; Division of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Hospital for Special Surgery, New York, New York, USA; University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford, UK.W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Jan van Breemen Research Institute/Reade; S. Wichuk, MD, Department of Medicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center, and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp. walter.maksymowych@ualberta.ca.
authors.forename: Walter P
authors.initials: WP
authors.lastname: Maksymowych
authors.affiliation: From the Department of Medicine, University of Alberta, Edmonton, Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University of Toronto, Toronto; Augurex Life Sciences Corp., North Vancouver, British Columbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam; Division of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Hospital for Special Surgery, New York, New York, USA; University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford, UK.W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Jan van Breemen Research Institute/Reade; S. Wichuk, MD, Department of Medicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center, and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp.
authors.forename: Gilles
authors.initials: G
authors.lastname: Boire
authors.affiliation: From the Department of Medicine, University of Alberta, Edmonton, Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University of Toronto, Toronto; Augurex Life Sciences Corp., North Vancouver, British Columbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam; Division of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Hospital for Special Surgery, New York, New York, USA; University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford, UK.W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Jan van Breemen Research Institute/Reade; S. Wichuk, MD, Department of Medicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center, and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp.
authors.forename: Dirkjan
authors.initials: D
authors.lastname: van Schaardenburg
authors.affiliation: From the Department of Medicine, University of Alberta, Edmonton, Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University of Toronto, Toronto; Augurex Life Sciences Corp., North Vancouver, British Columbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam; Division of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Hospital for Special Surgery, New York, New York, USA; University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford, UK.W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Jan van Breemen Research Institute/Reade; S. Wichuk, MD, Department of Medicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center, and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Wichuk
authors.affiliation: From the Department of Medicine, University of Alberta, Edmonton, Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University of Toronto, Toronto; Augurex Life Sciences Corp., North Vancouver, British Columbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam; Division of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Hospital for Special Surgery, New York, New York, USA; University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford, UK.W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Jan van Breemen Research Institute/Reade; S. Wichuk, MD, Department of Medicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center, and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp.
authors.forename: Samina
authors.initials: S
authors.lastname: Turk
authors.affiliation: From the Department of Medicine, University of Alberta, Edmonton, Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University of Toronto, Toronto; Augurex Life Sciences Corp., North Vancouver, British Columbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam; Division of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Hospital for Special Surgery, New York, New York, USA; University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford, UK.W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Jan van Breemen Research Institute/Reade; S. Wichuk, MD, Department of Medicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center, and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp.
authors.forename: Maarten
authors.initials: M
authors.lastname: Boers
authors.affiliation: From the Department of Medicine, University of Alberta, Edmonton, Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University of Toronto, Toronto; Augurex Life Sciences Corp., North Vancouver, British Columbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam; Division of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Hospital for Special Surgery, New York, New York, USA; University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford, UK.W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Jan van Breemen Research Institute/Reade; S. Wichuk, MD, Department of Medicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center, and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp.
authors.forename: Katherine A
authors.initials: KA
authors.lastname: Siminovitch
authors.affiliation: From the Department of Medicine, University of Alberta, Edmonton, Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University of Toronto, Toronto; Augurex Life Sciences Corp., North Vancouver, British Columbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam; Division of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Hospital for Special Surgery, New York, New York, USA; University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford, UK.W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Jan van Breemen Research Institute/Reade; S. Wichuk, MD, Department of Medicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center, and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp.
authors.forename: Vivian
authors.initials: V
authors.lastname: Bykerk
authors.affiliation: From the Department of Medicine, University of Alberta, Edmonton, Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University of Toronto, Toronto; Augurex Life Sciences Corp., North Vancouver, British Columbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam; Division of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Hospital for Special Surgery, New York, New York, USA; University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford, UK.W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Jan van Breemen Research Institute/Reade; S. Wichuk, MD, Department of Medicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center, and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp.
authors.forename: Ed
authors.initials: E
authors.lastname: Keystone
authors.affiliation: From the Department of Medicine, University of Alberta, Edmonton, Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University of Toronto, Toronto; Augurex Life Sciences Corp., North Vancouver, British Columbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam; Division of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Hospital for Special Surgery, New York, New York, USA; University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford, UK.W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Jan van Breemen Research Institute/Reade; S. Wichuk, MD, Department of Medicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center, and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp.
authors.forename: Paul Peter
authors.initials: PP
authors.lastname: Tak
authors.affiliation: From the Department of Medicine, University of Alberta, Edmonton, Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University of Toronto, Toronto; Augurex Life Sciences Corp., North Vancouver, British Columbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam; Division of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Hospital for Special Surgery, New York, New York, USA; University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford, UK.W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Jan van Breemen Research Institute/Reade; S. Wichuk, MD, Department of Medicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center, and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp.
authors.forename: Arno W
authors.initials: AW
authors.lastname: van Kuijk
authors.affiliation: From the Department of Medicine, University of Alberta, Edmonton, Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University of Toronto, Toronto; Augurex Life Sciences Corp., North Vancouver, British Columbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam; Division of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Hospital for Special Surgery, New York, New York, USA; University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford, UK.W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Jan van Breemen Research Institute/Reade; S. Wichuk, MD, Department of Medicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center, and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp.
authors.forename: Robert
authors.initials: R
authors.lastname: Landewé
authors.affiliation: From the Department of Medicine, University of Alberta, Edmonton, Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University of Toronto, Toronto; Augurex Life Sciences Corp., North Vancouver, British Columbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam; Division of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Hospital for Special Surgery, New York, New York, USA; University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford, UK.W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Jan van Breemen Research Institute/Reade; S. Wichuk, MD, Department of Medicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center, and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp.
authors.forename: Desiree
authors.initials: D
authors.lastname: van der Heijde
authors.affiliation: From the Department of Medicine, University of Alberta, Edmonton, Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University of Toronto, Toronto; Augurex Life Sciences Corp., North Vancouver, British Columbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam; Division of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Hospital for Special Surgery, New York, New York, USA; University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford, UK.W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Jan van Breemen Research Institute/Reade; S. Wichuk, MD, Department of Medicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center, and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp.
authors.forename: Mairead
authors.initials: M
authors.lastname: Murphy
authors.affiliation: From the Department of Medicine, University of Alberta, Edmonton, Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University of Toronto, Toronto; Augurex Life Sciences Corp., North Vancouver, British Columbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam; Division of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Hospital for Special Surgery, New York, New York, USA; University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford, UK.W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Jan van Breemen Research Institute/Reade; S. Wichuk, MD, Department of Medicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center, and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp.
authors.forename: Anthony
authors.initials: A
authors.lastname: Marotta
mesh_terms: D048948:14-3-3 Proteins / Q000276:immunology*; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000175:diagnosis* / Q000276:immunology; D001323:Autoantibodies / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000097:blood / Q000276:immunology; D012680:Sensitivity and Specificity
chemical_list: D048948:14-3-3 Proteins; D001323:Autoantibodies; D015415:Biomarkers
keywords: 14-3-3 PROTEINS; AUTOANTIBODIES; DIAGNOSIS; RHEUMATOID ARTHRITIS